Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1

The clinical risk-benefit profile of raloxifene derived from the intermediate endpoints of this study suggests that it may be a better alternative to ccEPT for preventing long-term postmenopausal health risks in healthy postmenopausal women who are not suffering from vasomotor symptoms.